## **Emilia Sato**

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1696142/publications.pdf

Version: 2024-02-01

		109137	143772
79	3,479	35	57
papers	citations	h-index	g-index
0.4	0.4	0.4	40.47
84	84	84	4247
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Pattern on the antinuclear antibody $\hat{a}\in HEp\hat{a}$ test is a critical parameter for discriminating antinuclear antibody $\hat{a}\in HEp\hat{a}$ positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis and Rheumatism, 2011, 63, 191-200.	6.7	272
2	Antimalarial treatment may have a timeâ€dependent effect on lupus survival: Data from a multinational Latin American inception cohort. Arthritis and Rheumatism, 2010, 62, 855-862.	6.7	177
3	Vitamin D deficiency in patients with active systemic lupus erythematosus. Osteoporosis International, 2009, 20, 427-433.	1.3	161
4	Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. Lupus, 1996, 5, 237-241.	0.8	118
5	Effects of supervised cardiovascular training program on exercise tolerance, aerobic capacity, and quality of life in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2005, 53, 838-844.	6.7	114
6	Childhood systemic lupus erythematosus in Latin America. The GLADEL experience in 230 children. Lupus, 2008, 17, 596-604.	0.8	108
7	Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatology, 2007, 46, 1560-1565.	0.9	104
8	Antiplatelet Therapy for the Prevention of Arterial Ischemic Events in Takayasu Arteritis. Circulation Journal, 2010, 74, 1236-1241.	0.7	104
9	Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2005, 52, 3073-3078.	6.7	102
10	First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, <i>Grupo Latino Americano de Estudio del) Tj ETQq0 0 0 Diseases, 2018, 77, 1549-1557.</i>	rgBT /Ove	erlock 10 Tf 50
11	Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL). Annals of the Rheumatic Diseases, 2017, 76, 2071-2074.	0.5	89
12	Estimating the incidence of systemic lupus erythematosus in a tropical region (Natal, Brazil). Lupus, 2002, 11, 528-532.	0.8	82
13	Scleroderma-like nailfold capillaroscopic abnormalities are associated with anti-U1-RNP antibodies and Raynaud's phenomenon in SLE patients. Lupus, 2002, 11, 35-41.	0.8	81
14	Short-term effect of leflunomide in patients with Takayasu arteritis: an observational study. Scandinavian Journal of Rheumatology, 2012, 41, 227-230.	0.6	71
15	Mortality Profile Related to Systemic Lupus Erythematosus: A Multiple Cause-of-death Analysis. Journal of Rheumatology, 2012, 39, 496-503.	1.0	64
16	Clinical implications of autoantibodies in HIV infection. Aids, 1997, 11, 1845-1850.	1.0	59
17	Methotrexate therapy in systemic lupus erythematosus. Lupus, 2001, 10, 162-164.	0.8	59
18	High prevalence of vertebral deformity in premenopausal systemic lupus erythematosus patients. Lupus, 2005, 14, 529-533.	0.8	57

#	Article	IF	CITATIONS
19	A Controlled Trial of Pulse Cydophosphamide Versus Pulse Methylprednisolone in Severe Lupus Nephritis. Lupus, 1994, 3, 107-112.	0.8	55
20	Lupus in Latin-American patients: lessons from the GLADEL cohort. Lupus, 2015, 24, 536-545.	0.8	54
21	Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases. Advances in Rheumatology, 2020, 60, 32.	0.8	53
22	Factors predictive of serious infections over time in systemic lupus erythematosus patients: data from a multi-ethnic, multi-national, Latin American lupus cohort. Lupus, 2019, 28, 1101-1110.	0.8	51
23	Leprosy-related joint involvement. Clinical Rheumatology, 2009, 28, 79-84.	1.0	46
24	Supervised physical exercise improves endothelial function in patients with systemic lupus erythematosus. Rheumatology, 2013, 52, 2187-2195.	0.9	45
25	IL-2, IL-5, TNF-α and IFN-γ mRNA expression in epidermal keratinocytes of systemic lupus erythematosus skin lesions. Clinics, 2011, 66, 77-82.	0.6	44
26	Demographic, clinical, and angiographic data of patients with Takayasu arteritis in Brazil. International Journal of Cardiology, 1998, 66, S67-S70.	0.8	43
27	Takayasu arteritis. International Journal of Cardiology, 2000, 75, S163-S166.	0.8	43
28	Myocardial perfusion scintigraphy and coronary disease risk factors in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2003, 62, 1066-1070.	0.5	43
29	Coronary artery angiography in systemic lupus erythematosus patients with abnormal myocardial perfusion scintigraphy. Arthritis and Rheumatism, 2003, 48, 3168-3175.	6.7	41
30	A Study of Multiple Causes of Death in Rheumatoid Arthritis. Journal of Rheumatology, 2015, 42, 2221-2228.	1.0	40
31	Leflunomida na arterite de Takayasu – Estudo observacional de longo prazo. Revista Brasileira De Reumatologia, 2016, 56, 371-375.	0.8	39
32	Long-term thalidomide use in refractory cutaneous lesions of systemic lupus erythematosus. Revista Da Associação Médica Brasileira, 1998, 44, 289-293.	0.3	37
33	Increased myeloperoxidase plasma levels in rheumatoid arthritis. Rheumatology International, 2012, 32, 1605-1609.	1.5	37
34	Consenso de lúpus eritematoso sistúmico. Revista Brasileira De Reumatologia, 2008, 48, 196-207.	0.8	35
35	Primary cardiac disease in systemic lupus erythematosus patients: protective and risk factorsdata from a multi-ethnic Latin American cohort. Rheumatology, 2014, 53, 1431-1438.	0.9	33
36	Impact of hypertension and hyperhomocysteinemia on arterial thrombosis in primary antiphospholipid syndrome. Lupus, 2007, 16, 782-787.	0.8	32

#	Article	IF	CITATIONS
37	Increased plasma myeloperoxidase levels in systemic lupus erythematosus. Rheumatology International, 2010, 30, 779-784.	1.5	32
38	Psychoanalytic psychotherapy improves quality of life, depression, anxiety and coping in patients with systemic lupus erythematosus: a controlled randomized clinical trial. Advances in Rheumatology, 2019, 59, 4.	0.8	30
39	Atherosclerotic plaque in carotid arteries in systemic lupus erythematosus: frequency and associated risk factors. Sao Paulo Medical Journal, 2005, 123, 137-142.	0.4	28
40	Anti-cyclic citrullinated peptide antibodies and rheumatoid factor in leprosy patients with articular involvement. Brazilian Journal of Medical and Biological Research, 2008, 41, 1005-1010.	0.7	26
41	Occasional Series: Lupus Around the World Systemic lupus erythematosus in São Paulo/Brazil: a clinical and laboratory overview. Lupus, 1995, 4, 100-103.	0.8	25
42	Oral microbial colonization in patients with systemic lupus erythematous: correlation with treatment and disease activity. Lupus, 2012, 21, 969-977.	0.8	24
43	Leflunomide in Takayasu arteritis – A long term observational study. Revista Brasileira De Reumatologia, 2016, 56, 371-375.	0.7	23
44	Risk factors for cardiovascular disease and endothelin-1 levels in Takayasu arteritis patients. Clinical Rheumatology, 2009, 28, 379-383.	1.0	22
45	Predictors of Remission and Low Disease Activity State in Systemic Lupus Erythematosus: Data from a Multiethnic, Multinational Latin American Cohort. Journal of Rheumatology, 2019, 46, 1299-1308.	1.0	21
46	Trends in dermatomyositis- and polymyositis-related mortality in the state of São Paulo, Brazil, 1985-2007: multiple cause-of-death analysis. BMC Public Health, 2010, 10, 597.	1.2	20
47	Predictive factors of flares in systemic lupus erythematosus patients: data from a multiethnic Latin American cohort. Lupus, 2018, 27, 536-544.	0.8	19
48	Brazilian urban population norms derived from the health-related quality of life SF-6D. Quality of Life Research, 2015, 24, 2559-2564.	1.5	18
49	C2 deficiency in blood donors and lupus patients: prevalence, clinical characteristics and HLA-associations in the Brazilian population. Lupus, 1997, 6, 462-466.	0.8	16
50	The effect of acute physical exercise on cytokine levels in patients with systemic lupus erythematosus. Lupus, 2013, 22, 1479-1483.	0.8	15
51	Perceptions of the population regarding generic drugs in Brazil: a nationwide survey. BMC Public Health, 2015, 15, 117.	1.2	14
52	A retrospective cohort study to assess PET-CT findings and clinical outcomes in Takayasu arteritis: does 18F-fluorodeoxyglucose uptake in arteries predict relapses?. Rheumatology International, 2020, 40, 1123-1131.	1.5	14
53	Skin is the most frequently damaged system in recent-onset systemic lupus erythematosus in a tropical region. Clinical Rheumatology, 2005, 24, 377-380.	1.0	13
54	Atorvastatin therapy reduces interferon-regulated chemokine CXCL9 plasma levels in patients with systemic lupus erythematosus. Lupus, 2010, 19, 927-934.	0.8	13

#	Article	IF	Citations
55	Factors predictive of high disease activity early in the course of SLE in patients from a Latin-American cohort. Seminars in Arthritis and Rheumatism, 2017, 47, 199-203.	1.6	11
56	High mobility group box 1 levels in large vessel vasculitis are not associated with disease activity but are influenced by age and statins. Arthritis Research and Therapy, 2015, 17, 158.	1.6	10
57	Prevalence of musculoskeletal symptoms in the five urban regions of Brazil—the Brazilian COPCORD study (BRAZCO). Clinical Rheumatology, 2016, 35, 1217-1223.	1.0	10
58	Transverse Myelitis in Systemic Lupus Erythematosus. Journal of Clinical Rheumatology, 2021, 27, S204-S211.	0.5	9
59	Atorvastatin reduced soluble receptors of TNF-alpha in systemic lupus erythematosus. Clinical and Experimental Rheumatology, 2016, 34, 42-8.	0.4	9
60	Visual loss resulting from immunosuppressive therapy in patients with syphilitic uveitis. Arquivos Brasileiros De Oftalmologia, 2015, 78, 185-6.	0.2	8
61	The relevance of performing exercise test before starting supervised physical exercise in asymptomatic cardiovascular patients with rheumatic diseases. Rheumatology, 2016, 55, 1978-1986.	0.9	8
62	Early discoid lupus erythematosus protects against renal disease in patients with systemic lupus erythematosus: longitudinal data from a large Latin American cohort. Lupus, 2017, 26, 73-83.	0.8	8
63	Elevation of soluble interleukin-2 receptor levels in the bronchoalveolar lavage from patients with systemic sclerosis. Rheumatology International, 2001, 21, 122-126.	1.5	7
64	The Influence of Income and Formal Education on Damage in Brazilian Patients With Systemic Lupus Erythematosus. Journal of Clinical Rheumatology, 2017, 23, 246-251.	0.5	7
65	Therapeutic Guidelines for Latin American Lupus Patients. Journal of Clinical Rheumatology, 2018, 24, 41-44.	0.5	7
66	Long-term persistence of anti- $\hat{l}^2$ 2 glycoprotein I in treated leprosy patients. Lupus, 2014, 23, 1249-1251.	0.8	6
67	Evaluation of functional capacity in individuals with signs and symptoms of musculoskeletal disease: results of the BRAZCO population study (Brazilian COPCORD Study). Rheumatology International, 2015, 35, 1873-1879.	1.5	5
68	Chronic use of hydroxychloroquine did not protect against COVID-19 in a large cohort of patients with rheumatic diseases in Brazil. Advances in Rheumatology, 2021, 61, 60.	0.8	5
69	Autoimmune/autoinflammatory syndrome induced by adjuvants: a focus on silicone. Clinical Rheumatology, 2022, 41, 3275-3283.	1.0	5
70	Jaccoud's arthropathy in SLE: findings from a Latin American multiethnic population. Lupus Science and Medicine, 2019, 6, e000343.	1.1	4
71	Adolescentes com Lúpus Eritematoso Sistêmico: um estudo por meio do método de rorschach. Psicologia: Teoria E Pesquisa, 2004, 20, 145-151.	0.1	4
72	Different epidemiologic profiles of systemic vasculitis between Brazil and Peruâ€"preliminary results in two referral centers from both countries. Clinical Rheumatology, 2022, 41, 635-639.	1.0	4

#	Article	IF	CITATIONS
73	Serum Myostatin and Follistatin Levels in Patients With Dermatomyositis and Polymyositis. Journal of Clinical Rheumatology, 2022, 28, 33-37.	0.5	3
74	Endothelial progenitor cells and vascular endothelial growth factor in patients with Takayasu's arteritis. Advances in Rheumatology, 2018, 58, 24.	0.8	2
75	Ramipril Improves Endothelial Function and Increases the Number of Endothelial Progenitor Cells in Patients With Systemic Lupus Erythematosus. Journal of Clinical Rheumatology, 0, Publish Ahead of Print, .	0.5	2
76	Vena cava thrombosis associated with nephrotic syndrome in the puerperal gestational cycle. Sao Paulo Medical Journal, 2001, 119, 24-28.	0.4	1
77	Systemic vasculitis: a difficult diagnosis. Sao Paulo Medical Journal, 1997, 115, 1418-1421.	0.4	1
78	Comment on: Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial: reply. Rheumatology, 2007, 47, 382-383.	0.9	0
79	Factors associated with neuropsychiatric involvement in Latin American patients with systemic lupus erythematosus. Lupus, 2021, 30, 096120332110203.	0.8	0